Search

Your search keyword '"Calleja, Jose Luis"' showing total 313 results

Search Constraints

Start Over You searched for: Author "Calleja, Jose Luis" Remove constraint Author: "Calleja, Jose Luis"
313 results on '"Calleja, Jose Luis"'

Search Results

1. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

5. Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B

6. Evolution of spontaneous portosystemic shunts over time and following aetiological intervention in patients with cirrhosis

7. Porto-sinusoidal vascular liver disorder with portal hypertension: Natural history and long-term outcome

9. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease

10. Characterizing Hepatitis Delta in Spain and the gaps in its management

12. Predicting survival in patients with ‘non-high-risk’ acute variceal bleeding receiving β-blockers+ligation to prevent re-bleeding

13. PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B

14. Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver

15. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial

16. Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis

17. Research Priorities for Precision Medicine in NAFLD

19. Consenso AEEH «Consenso sobre métodos de detección y derivación de enfermedades hepáticas prevalentes ocultas»

20. Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors

21. Recomendaciones para el diagnóstico integral de las hepatitis virales crónicas en una única extracción analítica

22. Incidence and factors predictive of recurrent thrombosis in people with non-cirrhotic portal vein thrombosis

25. Real‐life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.

26. Mild AST elevation as an early sign of COVID-19 severity in a multicenter Madrid cohort

27. Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B

28. Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury

32. Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data

33. Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B

34. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

35. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH

37. Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis

38. Predicting survival in patients with ‘non-high-risk’ acute variceal bleeding receiving β-blockers+ligation to prevent re-bleeding

39. Eliminación de la hepatitis C. Documento de posicionamiento de la Asociación Española para el Estudio del Hígado (AEEH)

40. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis

42. Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH)

45. Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules

47. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis

48. PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B

50. Linfoma primario de colon.

Catalog

Books, media, physical & digital resources